Since control of diabetes and obesity are significant health outcome risk factors, it is conceivable that the shortages and high cost of GLP1 agonists will exacerbate existing health disparities. David Cutler, MD His perspective echoed what Ma told us, namely that [o]ne of the biggest bottlenecks with GLP-1RA access is cost and insurance. Even if a doctor prescribes [this type of drug], patients cannot obtain it if their insurance does not cover it, which could worsen disparities, especially for those with public insurance or in underserved populations, he also emphasized
Dr Joseph Pizzorno, one of the founders of Bastyr University, wrote a paper called: Homocysteine: Friend or Foe
Tirzepatide's potent glucose-lowering effects often outweigh niacin's modest hyperglycemic impact
Both the Wegovy pill and injection are eligible for insurance
The study used a reserpine-induced fibromyalgia model in rats, which is a well-established way of producing fibromyalgia-like symptoms in animals
Hepatomegaly and midline abdominal tenderness (as seen in acute pancreatitis) may be detected on physical examination with a report of deceased urinary output
